Clinical Significance of Human Herpesvirus 6 and 7 Infection in a Tertiary Hospital: a Case-Control Study
Abstract BackgroundHuman herpesviruses (HHV)-6 and HHV-7 are ubiquitous viruses with a global seroprevalence of around 90%, but their pathogenic significance remains unclear. MethodsFor 2 years, at our center, the presence of HHV6 and 7 DNA was investigated by PCR assay in blood, CSF, or other fluids. Epidemiological and clinical variables were collected from these patients and compared with those obtained in a negative-control cohort. Molecular detection of herpesvirus was performed using The Clart Entherpex kit (Genomica, Coslada, Spain), allowing simultaneous detection and identification of the eight human herpesviruses (HSV-1 to HHV-8) and Enterovirus (echovirus, poliovirus, and coxsackievirus).ResultsAll patients, cases, and controls were immunocompromised and had similar baseline clinical conditions. For all of them, molecular amplification of HHV-6 or 7 was requested as a diagnostic complement from different clinical pictures, mainly neurological symptomatology (80%). Corticosteroid treatment and viral or bacterial co-infection were independently associated with HHV-6 or 7 infections. When the impact of both viruses was analyzed independently, it was confirmed that HHV-6 was independently associated with higher 1-year mortality. ConclusionHHV-6 replication in CSF or blood may be a surrogate marker of mortality in the medium term in immunocompromised patients..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ResearchSquare.com - (2023) vom: 07. März Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Borque, Pablo [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-1918759/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA03680858X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA03680858X | ||
| 003 | DE-627 | ||
| 005 | 20230429190250.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220809s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-1918759/v1 |2 doi | |
| 035 | |a (DE-627)XRA03680858X | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-1918759/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Borque, Pablo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Significance of Human Herpesvirus 6 and 7 Infection in a Tertiary Hospital: a Case-Control Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract BackgroundHuman herpesviruses (HHV)-6 and HHV-7 are ubiquitous viruses with a global seroprevalence of around 90%, but their pathogenic significance remains unclear. MethodsFor 2 years, at our center, the presence of HHV6 and 7 DNA was investigated by PCR assay in blood, CSF, or other fluids. Epidemiological and clinical variables were collected from these patients and compared with those obtained in a negative-control cohort. Molecular detection of herpesvirus was performed using The Clart Entherpex kit (Genomica, Coslada, Spain), allowing simultaneous detection and identification of the eight human herpesviruses (HSV-1 to HHV-8) and Enterovirus (echovirus, poliovirus, and coxsackievirus).ResultsAll patients, cases, and controls were immunocompromised and had similar baseline clinical conditions. For all of them, molecular amplification of HHV-6 or 7 was requested as a diagnostic complement from different clinical pictures, mainly neurological symptomatology (80%). Corticosteroid treatment and viral or bacterial co-infection were independently associated with HHV-6 or 7 infections. When the impact of both viruses was analyzed independently, it was confirmed that HHV-6 was independently associated with higher 1-year mortality. ConclusionHHV-6 replication in CSF or blood may be a surrogate marker of mortality in the medium term in immunocompromised patients. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Galán, Juan Carlos |4 aut | |
| 700 | 1 | |a Romero, Beatriz |4 aut | |
| 700 | 1 | |a Gioia, Francesca |4 aut | |
| 700 | 1 | |a Escudero, Rosa |4 aut | |
| 700 | 1 | |a Martín-Dávila, Pilar |4 aut | |
| 700 | 1 | |a Moreno, Santiago |4 aut | |
| 700 | 1 | |a Fortún, Jesús |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 07. März |
| 773 | 1 | 8 | |g year:2023 |g day:07 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-1918759/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 07 |c 03 | ||